Neogen Corporation  

(Public, NASDAQ:NEOG)   Watch this stock  
Find more results for NEOG
55.35
+1.35 (2.50%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 54.07 - 55.42
52 week 37.26 - 55.42
Open 54.18
Vol / Avg. 77,451.00/66,014.00
Mkt cap 1.32B
P/E 51.24
Div/yield     -
EPS 1.08
Shares 23.92M
Beta 0.69
Inst. own 82%
Jul 22, 2013
Q4 2013 Neogen Earnings Release Add to calendar
Mar 26, 2013
Q3 2013 Neogen Earnings Conference Call
Mar 25, 2013
Q3 2013 Neogen Earnings Release
Mar 18, 2013
Neogen at Roth Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Feb '13) 2012
Net profit margin 12.95% 12.23%
Operating margin 18.93% 18.33%
EBITD margin - 21.69%
Return on average assets 9.63% 9.55%
Return on average equity 11.05% 11.05%
Employees 746 -
Carbon Disclosure Rating - -

Address

620 Lesher Place
LANSING, MI 48912
United States - Map
+1-517-3729200 (Phone)
+1-517-3722006 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Neogen Corporation (Neogen), together with its subsidiaries, develops, manufactures, and markets a diverse line of products dedicated to food and animal safety. It is engaged in developing and marketing test kits that provide food safety solutions. The Company�s food safety segment consists primarily of diagnostic test kits and complementary products (dehydrated culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. These products are marketed in North America, the United Kingdom and other parts of Europe, Mexico and Brazil and by distributors through the rest of the world. In October 2012, it acquired the stock of Macleod Pharmaceuticals. In January 2013, the Company acquired the assets of Scidera Genomics, LLC.

Officers and directors

James L. Herbert Chairman of the Board, Chief Executive Officer
Age: 72
Bio & Compensation  - Reuters
Lon M. Bohannon President, Chief Operating Officer, Director
Age: 59
Bio & Compensation  - Reuters
Steven J. Quinlan CPA Chief Financial Officer, Vice President
Age: 48
Bio & Compensation  - Reuters
Terri A. Morrical Vice President - Animal Safety Operations
Age: 47
Bio & Compensation  - Reuters
Edward L. Bradley Vice President - Food Safety
Age: 52
Bio & Compensation  - Reuters
Kenneth V. Kodilla Vice President - Manufacturing
Age: 55
Bio & Compensation  - Reuters
Jason W. Lilly Ph. D. Vice President - Corporate Development
Age: 38
Bio & Compensation  - Reuters
Joseph M. Madden Ph.D. Vice President - Scientific Affairs
Age: 63
Bio & Compensation  - Reuters
Jennifer A. Rice Ph.D. Vice President & Senior Research Director
Age: 51
Bio & Compensation  - Reuters
Mark A. Mozola Ph.D. Vice President - Research & Development
Age: 56
Bio & Compensation  - Reuters